Genzyme To Present Aubagio (teriflunomide) And Lemtrada (alemtuzumab) Data At CMSC
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company, announced today that data on its relapsing multiple sclerosis treatments, Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab), will be featured during the 2015 annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC) being held in Indianapolis, Indiana, May 27-30.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.